RxDoctor Payments Data

Lynnette Brown, MD

Internal Medicine · Catonsville, MDNPI 1508010539

Payments from drug & device makers

$1,763in general payments, 2019–2025

Across 70 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$448
  • Amgen$174
  • Abbott$152
  • Exact Sciences$144
  • Merck$139
  • AbbVie$105
  • plus $601 from 14 others

What the payments were for

  • Food & beverage$1,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,763 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$120,624
Medicare patients
183
Services billed
1,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide16$31,152
EliquisApixaban22$25,026
JardianceEmpagliflozin16$23,894
OzempicSemaglutide13$18,405
JanuviaSitagliptin Phosphate13$13,620
FarxigaDapagliflozin Propanediol11$11,960
EntrestoSacubitril/Valsartan12$7,988
Atorvastatin Calcium126$3,090
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,413
Amlodipine Besylate190$1,642
Rosuvastatin Calcium30$1,085
Albuterol Sulfate HfaAlbuterol Sulfate33$946
Valsartan17$928
Metoprolol Succinate38$788
Fluoxetine Hcl17$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$45$31,15216 claims
PfizerEliquis$73$25,02622 claims
Novo NordiskOzempic$448$18,40513 claims
MerckJanuvia$139$13,62013 claims
AstraZenecaFarxiga$103$11,96011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →